Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

Weight loss jabs will be given to 3,000 people in a trial to explore whether they can get people back into work, The i Paper understands. A five-year trial of the weight loss drug tirzepatide in ...

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

Citation: Tirzepatide produces clinically meaningful weight loss for at least 3 years in non-diabetic overweight adults: Trial (2025, April 14) retrieved 20 July 2025 from https://medicalxpress ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their prescribed obesity medication, according to findings published in Obesity.

HealthDay News — For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7% on average, which is lower than the percentages reported ...

Not only did people taking tirzepatide lose more weight overall, but more of them reached key weight-loss milestones. Nearly one-third of tirzepatide users lost at least 25% of their body weight.

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...

New research reveals weight-loss drugs help during treatment but weight returns rapidly after stopping. Experts urge ...

Eli Lilly's tirzepatide leads to 50% more weight loss compared to Novo Nordisk's semaglutide in 72-week study. ... Clinical trial participants who took tirzepatide, the drug sold as Zepbound, ...

In real-world cohort, percentage weight reduction at one year was 3.6, 6.8, and 11.9 percent with early and late discontinuation and nondiscontinuation, respectively.

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds ... Weight loss was about 6% lower in men than in women in both groups, ...